Investors & Media

Press Releases

Date Title View
Toggle Summary SAGE Therapeutics to Participate in the 2014 Leerink Partners Rare Disease Roundtable
CAMBRIDGE, Mass. , Sept. 25, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced management will participate in the 2014 Leerink
View HTML
Toggle Summary SAGE Therapeutics Appoints Michael F. Cola to the Company's Board of Directors
Cola Brings Industry and Leadership Expertise to SAGE's Advancing Clinical Assets
View HTML
Toggle Summary SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs
Data Highlight Potential of SAGE-217 to Address Acute and Chronic Forms of Epilepsy and Seizure Disorders CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ: SAGE) today presented preclinical data on its second-generation neuroactive steroid, SAGE-217, at the Twelfth Eilat Conference on
View HTML
Toggle Summary SAGE Therapeutics Reports Second Quarter 2014 Financial Results
Successfully Completed Initial Public Offering and Reported Preliminary Results for SAGE-547 in Super-Refractory Status Epilepticus CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening,
View HTML
Toggle Summary SAGE Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeffrey Jonas , M.D., chief executive officer, will present at
View HTML
Toggle Summary SAGE Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics , a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public
View HTML
Toggle Summary SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
Designation Underscores Unmet Medical Need for Life-Threatening Seizure Condition CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today
View HTML
Toggle Summary SAGE Therapeutics Announces Full Exercise of Over-Allotment Option
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the underwriters of its initial public offering (IPO) exercised in full their
View HTML
Toggle Summary SAGE Therapeutics Announces Pricing of Initial Public Offering View HTML
Toggle Summary SAGE Therapeutics Appoints James M. Frates to the Company's Board of Directors View HTML